Significantly, CD44+/CD24−/Low CSCs displayed a higher resistance to methotrexate while they where highly sensitive to the Cdk2 inhibitor SU9516 compared to bulk SUM149PT cancer cells (Fig. 3). This evidence concerns the gene CDK2 and cancer.